VNDA · Vanda Pharmaceuticals Inc.
$4.83
-0.08 (-1.63%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$305.34M
Shares
60.46M
Volume · Sep 30
3.08M
Avg daily vol (3M)
940.18K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.91
Open$5.16
Day$4.90–5.19
52W close$4.32–9.56
Avg vol 30d914K
Short int8.5M · 14.1% float · 12.1d
Short vol58%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$215.72M
Trailing 12 months
Net income (TTM)
−$274.85M
Trailing 12 months
Revenue growth YoY
-3.9%
Year over year
Operating margin
-86.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-46.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$55.88M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+2.4%
Trailing year
Short interest
14.1%
Latest settlement · 12.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Vanda reported strong Fanapt growth (Q2 sales up 23% YoY, TRx up 31%) but HETLIOZ sales fell 66% on generic competition, and net loss widened to $62.5M; the company reiterated its 2026 total revenue guidance of $240–$290M and expects operating expenses to begin moderating by year-end 2026 with cash runway through end of 2027.
Bullish
- + Management reiterated 2026 total revenue guidance of $240–$290M, implying ~23% growth over 2025.
- + BYSANTI was FDA-approved for bipolar I disorder and schizophrenia with launch expected in 2H 2026.
- + Quimilza BLA has a December 12, 2026 PDUFA date and was recommended for orphan drug designation by the EU EMA.
Bearish
- − HETLIOZ Q2 net product sales fell 66% YoY to $5.6M due to generic competition.
- − NEREUS launch produced only $1M of recognized Q2 revenue with $12.6M constrained amid elevated wholesaler inventory.
- − Q2 total revenue declined 4% YoY to $50.5M and excludes ~$7M of HETLIOZ orders that will shift to Q3.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−6%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−33%
trailing
YTD return
−44%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.05% of float · ▲ +10.5% MoM · 12.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
172 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+9%
Y/Y
EPS growth
−1033%
Y/Y
Free cash flow
$-110.4M
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Total revenues
· Full Year 2026
Initiated
$240M – $290M
prior FY $216.11M
midpoint +22.6% Y/Y
Fanapt® and BYSANTI™ net product sales
· Full Year 2026
Initiated
$150M – $170M
Other net product sales
· Full Year 2026
Initiated
$80M – $90M
Fanapt® and BYSANTITM net product sales
· Full Year 2026
Initiated
$150M – $170M
NEREUSTM net product sales
· Full Year 2026
Initiated
$10M – $30M
Guided vs delivered
· last 1 settled
Total revenues
Full Year 2024
guided $180M – $210M
$198.77M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.05% of float · ▲ +10.5% MoM · 12.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
172 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $5 · 11%
Range high $10
vs 200-day avg -25%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VNDA
this stock
Vanda Pharmaceuticals Inc.
|
$305.34M | -44.3% | +8.7% | — | 14.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VNDA | -2.6% | -9.4% | -33.0% | -9.1% | -44.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -1.9% | -9.5% | -45.2% | -8.5% | -56.2% |